ABOUT OUR PRODUCTS

Are you interested in loosing weight like magic? Are you interested in achieving your dream body? Are you tired of been insulted by the society?

These products are here for you. You are one step to achieving your most wanted desires. We have WEGOVY, TRULICITY, SAXENDA, OZEMPIC for you. 

Advantages of ordering from us,

You can buy Saxenda, Wegovy, Trulicity, and Ozempic with and without prescribtions.

You will have the opportunity to be guided by us during all the cycle.

We are specialised weight loss specialist and have over 9 years experiece, So count yourself lucky for coming across our website.

visit our store
buy wegovy

WEGOVY

buy wegovy
buy wegovy

Wegovy weight loss Medication Characteristics:

Wegovy is a once-weekly injectable weight loss aid that is frequently prescribed when other weight loss attempts have failed. It is sold both with and without a prescription.
 
All patients on their weight loss journey receive confidential follow-up and advice from us.
 
**Our clinical team is well-versed in WeGovy and is happy to assist with any questions.**
 

What’s on this page?

  • Buy Wegovy weight loss
  • What is Wegovy Weight Loss Injection?
  • How Does Wegovy Work?
  • Can Wegovy Help me Lose Weight?
  • Wegovy Vs Saxenda
  • ozempic vs wegovy
  • Wegovy and Pregnancy
  • Wegovy Summary
  • Wegovy Alternatives

Buy Wegovy Weight Loss;

Wegovy was recently approved by the FDA, the United States’ medicines regulator, to aid in weight loss. It is an injection that, like the Saxenda weight loss pen, can be used to suppress your appetite and thus aid in your weight loss journey. The only difference between Saxenda and Wegovy is that Saxenda is administered once daily, whereas Wegovy is administered once weekly.

What is Wegovy – What is Wegovy Weight Loss Injection?

Wegovy is a weight loss injection available only by prescription. The active ingredient in Wegovy is semaglutide, which is also found in Ozempic. Ozempic differs from Wegovy in that it is only licensed for diabetics and comes in a different strength than Wegovy, which comes in a single strength of 2.4mg.
 
Wegovy (semaglutide) injection 2.4 mg is an injectable prescription medicine used to help adults who are obese (BMI 30) or overweight (BMI 27) and have weight-related medical problems (e.g. high blood pressure, type 2 diabetes, high cholesterol) lose weight and keep it off.
 
  • Wegovy should only be used in conjunction with a low-calorie diet and regular exercise. Wegovy alone will not help you lose weight if you do not make other lifestyle changes.

 

  • Wegovy contains semaglutide, a GLP-1 receptor agonist, and should NOT be combined with other GLP-1 agonists like Saxenda or Ozempic.

 

  • There isn’t enough information to say whether taking Wegovy with other prescription, over-the-counter, or herbal weight loss products is safe and/or effective.

How does wegovy work?

Wegovy (semaglutide 2.4mg) is a weight loss treatment that is self-injectable. It contains the active ingredient semaglutide, which is very similar to a naturally occurring hormone in the human body called Glucagon-Like Peptide 1 (GLP-1), which belongs to the incretin hormone family.
 
GLP-1 is naturally released from your intestines after a meal to help regulate blood sugar levels and reduce the amount of glucagon in your body. Glucagon is a hormone that occurs naturally and works by inhibiting the action of insulin. As a result, it makes you feel less hungry, slows stomach emptying, and keeps you feeling ‘fuller’ for longer.
To summarize, Wegovy ‘tricks’ your body into producing more GLP-1, which signals to your brain that you are full and do not need to eat.
 

Can Wegovy Help me Lose Weight?

Novo Nordisk conducted a Step 1 clinical trial for Wegovy that included 1,961 patients with obesity (BMI 30 kg/m2) or overweight (BMI 27 kg/m2-29.9 kg/m2) and at least one weight-related comorbid condition, such as treated or untreated dyslipidemia or hypertension. Throughout the trial, patients received Wegovy or placebo, as well as instructions for a reduced-calorie diet (approximately 500 kcal/day deficit) and increased physical activity counseling (recommended to a minimum of 150 min/week).

After 68 weeks, the trial resulted in a statistically significant reduction in body weight when compared to the placebo. The trial found that patients taking Wegovy lost 14.8% of their body weight on average, compared to 2.8% for those taking the placebo, who only reduced their calorie intake and increased their physical activity.
 
In addition, after 68 weeks on Wegovy, 83.5% of patients lost 5% or more of their body weight. In the placebo group, 31.1% of patients lost 5% or more of their weight. Additional clinical trials were also conducted, and the results showed statistically significant weight loss.

Wegovy vs Saxenda

Saxenda (liraglutide) injection 3 mg is an injectable prescription medicine that may aid in the weight loss and maintenance of some adults with excess weight (BMI 27) who also have weight-related medical problems or obesity (BMI 30). Saxenda should be used in conjunction with a low-calorie diet and increased physical activity.
 
Wegovy and Saxenda are both GLP-1 receptor agonists that belong to the same class of injectable hormone-like drugs. The main difference between the two is that Saxenda is administered once DAILY, whereas Wegovy is administered once WEEKLY.
 

Wegovy and Pregnancy

Wegovy may cause fetal harm. When pregnancy is recognized, discontinue Wegovy. Discontinue Wegovy in patients at least 2 months before a planned pregnancy.

Ozempic vs Wegovy;

In some patients, Ozempic is used to treat type 2 diabetes and prevent major cardiovascular problems, whereas Wegovy is used for chronic weight management and weight loss.
 
The table below lists the specific conditions that Ozempic and Wegovy are used to treat, as well as the dosage forms and strengths available for each semaglutide-containing product.
 

 

Ozempic

Wegovy

Generic name

Semaglutide 

Semaglutide

Marketed by

Novo Nordisk

Novo Nordisk

Dosage form and strength

Injection – 2mg/1.5ml (1.34mg/ml)

  • Single-patient-use pens (delivering 0.25mg or 0.5mg, or 1mg per injection)

Injection – 4 mg/3ml (1.34mg/ml)

  • Single-patient-use pen (delivering 1mg per injection)

Injection – 8 mg/3ml (2.68mg/ml)

  • Single-patient-use pen (delivering 2mg per injection)

Dose is increased slowly up to a maximum of 2mg weekly if required

Injection – pre-filled, single-dose pen delivering doses of 0.25, 0.5, 1.7 or 2.4mg).

Dose is increased slowly until a maintenance dose of 2.4mg weekly is reached

Uses

  • As an add on to diet and exercise to improve glycemic control in adults with type 2 diabetes

  • To reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease

An an add-on to a reduced calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of:

  • 30kg/m2 or greater (obesity) or

  • 27kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition, such as high blood pressure, type 2 diabetes and dyslipidemia

As an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in pediatric patients aged 12 years and older with:

  • an initial BMI at the 95th percentile or greater for age and sex (obesity).

First approved in US

2017

2021

Wegovy alternatives.

Wegovy alternatives include Orlistat and Saxenda, which is the most similar medicine to Wegovy because it works in the same way and is manufactured by Novo Nordisk. Saxenda, unlike Wegovy, is administered once daily.

People who improve their diet and exercise may fail to lose weight for a variety of reasons. These people may benefit from medications such as WEGOVY, TRULICITY, SAXENDA, OZEMPIC
 
buy wegovy

Wegovy Dosage.

To achieve the best weight-loss results with Wegovy, you must take the full dose and stick to it.
 
Wegovy is available in five different dose strengths. Wegovy is started at 0.25 mg once a week and increased every 4 weeks until the full dose of 2.4 mg is reached. It’s critical to stick to the dosing schedule prescribed by your doctor.
wegovy dosage

Wegovy Side Effects.

The most commonly reported side effects in clinical trials were:

  • Nausea (reported in 44% of patients)
  • Diarrhoea (reported in 30% of patients)
  • Vomiting (reported in 24% of patients)
  • Constipation (reported in 24% of patients)
Abdominal pain, headache, fatigue, and dizziness were among the other side effects.
 
Semaglutide was linked to an increased risk of thyroid cancer in animal studies. Although this link has not been established in humans, Wegovy should not be used by people who have a personal or family history of thyroid cancer or a condition known as MEN-2.
 
Wegovy has also been linked to serious side effects such as acute pancreatitis, gallbladder disease, increased heart rate, and kidney injury. For more information on side effects, visit the Wegovy website.

Wegovy Warning and Precautions.

All medications have risks, even if they are minor- the following is a comprehensive list of all potential complications, warnings, and precautions to be considered when being prescribed Wegovy.
 
  • Thyroid C-Cell Tumors: Patients should be evaluated further if serum calcitonin levels are elevated or thyroid nodules are found on physical examination or neck imaging.

 

  • Acute Pancreatitis: Patients treated with GLP-1 receptor agonists, including semaglutide, have experienced acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis. In clinical trials, patients treated with Wegovy experienced acute pancreatitis. Examine patients for signs and symptoms of acute pancreatitis (including persistent severe abdominal pain, sometimes radiating to the back, and which may or may not be accompanied by vomiting). If acute pancreatitis is suspected, discontinue Wegovy immediately, and do not restart if acute pancreatitis is confirmed.

 

  • Acute Gallbladder Disease: Cholelithiasis was reported by 1.6% of WegovyTM patients and 0.7% of placebo patients in clinical trials. 0.6% of WegovyTM patients and 0.2% of placebo patients reported cholecystitis. Gallbladder studies and appropriate clinical follow-up are recommended if cholelithiasis is suspected.

 

  • Wegovy lowers blood glucose and can cause hypoglycemia. Hypoglycemia was reported in 6.2% of Wegovy patients versus 2.5% of placebo patients in a trial of type 2 diabetes patients. Patients with type 2 diabetes who use Wegovy in conjunction with an insulin secretagogue (e.g., sulfonylurea) or insulin may experience an increased risk of hypoglycemia, including severe hypoglycemia. Inform patients about the dangers of hypoglycemia and teach them about the signs and symptoms. Blood glucose levels in type 2 diabetes patients should be monitored.
buy wegovy